Aruvant Sciences is a clinical stage biotech company focused on developing innovative gene therapies for patients suffering with hemoglobinopathies.
The lead candidate in Aruvant’s pipeline, ARU-1801, is an investigational gene therapy for sickle cell disease and beta thalassemia.
ARU-1801 utilizes proprietary technology intended to increase functioning red blood cells by inserting a modified fetal hemoglobin gene into autologous stem cells through a lentiviral vector. Furthermore, the Reduced Intensity Conditioning (RIC) regimen of ARU-1801 has been designed to improve patient experience and access.
ARU-1801 is currently being investigated in a Phase 1/2 clinical study. Two patients have been dosed in the study so far, both of whom have shown promising results.
Aruvant is led by a team with a successful track record of identifying innovative therapies and rapidly executing on clinical development plan to deliver value to patients.